72 results about "Peptide expression" patented technology

The invention generally relates to a bone growth factor, and more particularly to compositions including NELL1, articles of manufacture including NELL1 and methods of using NELL1 to induce bone formation. This invention also provides methods for the expression and purification of NELL1 and NELL2 peptides.

This invention is directed to methods for manipulating sex, reversing sex, changing sex ratio, or moderating crustacean androgenic gland peptide expression in crustaceans for producing a monosex culture. In one embodiment, the present method comprises the step of injecting a dsRNA for the gene of IAG into a male crustacean. In another embodiment, the present method comprises the step of injecting a dsRNA for the gene of IAG into a female crustacean that had acquired a spermatophore (a sperm sac) after mating with a male. In another embodiment, the present invention provides a method of producing a monosex culture of crustacean by introducing a recombinant IAG peptide into the female crustacean, thereby obtains male with altered sexual characteristics for mating with a normal female. In one embodiment, the crustacean is a shrimp or lobster.

The invention is directed to expression of non-plant proteins in rice plants. Expression is optimized by use of a non-rice promoter of a monocot protein gene and its corresponding signal peptide for expression of the non-plant protein in rice plant at high yields. The invention is useful for making human proteins, polypeptides and peptides in rice seeds. The expressed protein product can be isolated from the rice seed for administration to humans or other animals.

The invention is directed to methods and metric suitable for use in modulating the expression of a polypeptide encoded by a nucleic acid sequence. In certain aspects, the invention also relates to methods for introducing modifications in a polypeptide, for example through substitution of one or more nucleic acids in an untranslated sequence or in a coding sequence of a nucleic acid sequence encoding a polypeptide to increase the expression of the polypeptide.

The invention provides a recombinant phage double expression vector and application, relating to the technical field of biology. The recombinant phage double expression vector is a recombinant double expression vector obtained after inserting a target gene 1 into the downstream part of a gene p10B in a T7 phage genome and inserting a eukaryotic expression cassette containing a target gene 2 into a non-coding region in the T7 phage genome. The recombinant phage double expression vector has high stability, can display the protein coded by the target gene 1 on the surface of the phage, simultaneously can transfer the eukaryotic expression cassette into an immune cell to achieve eukaryotic expression of the target gene 2, and can serve as a common platform for expression of various epitopes, namely polypeptides. Immune efficacy detection finds that bodies can generate high-level VP1 structural protein antibodies against foot and mouth disease viruses after being immunized by the vaccine, and the antibodies have long duration.

Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.

The invention discloses a method for detecting serum polypeptide for kidney transplantation rejection. The method comprises the following steps of: 1, classifying the previously collected serum samples according to the seriousness of the disease of a donor; 2, capturing the polypeptide from the serum in the serum sample groups by using MB-WCX respectively and concentrating the polypeptide on magnetic balls to form tie molecules; 3, eluting the tie molecules from the magnetic balls and performing MALDI-TOF mass spectrometric analysis; classifying the different peptide peaks measured from the samples of each group to establish a classifying and predicting model so as to acquire a difference peptide expression map; 4, combining the serum samples of a kidney transplantation rejection patient to be detected by using the MB-WCX, then performing the MALDI-TOF mass spectrometric analysis and comparing the analysis result with the map acquired in the step 3 so as to mark the peptide of the serum sample. The method contributes to understanding the pathogenesis for the kidney transplantation rejection well from the level of the proteomics and makes the early diagnosis of the kidney transplantation rejection possible.

Disclosed are compositions and methods for expressing and purifying a peptide of interest using a Flagellar Type III secretion system. Disclosed are nucleic acid sequences that contain a FlgM nucleic acid sequence, a cleavage site, and a nucleic acid sequence of interest. Also disclosed are polypeptides that contain FlgM, a cleavage site and a peptide of interest. Methods of producing polypeptides that have FlgM, a cleavage site and a peptide of interest are provided.

The invention provides expression vectors that support high levels of polypeptide expression in mammalian cells. The vectors contain at least one expression cassette for a target polypeptide; an expression cassette for a eukaryotic selectable marker protein; an expression cassette for a bacterial selectable marker protein, and a bacterial plasmid origin of replication.

The invention discloses a method for producing a simeglutide precursor by high-density fermentation of recombinant escherichia coli. In order to solve the problem that the expression quantity of semeglutide produced through fermentation at present is low, the Mg ion concentration is remarkably increased in a high-density fermentation culture medium of prepared recombinant escherichia coli for expressing a semeglutide precursor, the induction OD value of fermentation culture is increased to 150 or above, the fermentation OD value of the recombinant escherichia coli and the thallus biomass of inclusion bodies are remarkably increased, the high-density fermentation effect of the recombinant engineering bacteria is realized, and the expression quantity of a semeglutide precursor is obviously increased.

Methods and compositions are provided for diagnosing ectopic pregnancy in a mammalian subject by detecting changes in expression of ISM2, ADAM12, PST1, PSG7, PST11, PSG9, PSG2 and other genes identified therein, including combinations thereof. A selected gene, gene transcript or protein/peptide expression product, or profiles or signatures formed by combinations of same, detected in a biological fluid of a subject, enables comparison of the corresponding genes, proteins or profiles from that of a reference or control having a normal intrauterine pregnancy. Detection of characteristic changes in the gene profile or protein expression signature of the subject is correlated with a diagnosis of ectopic pregnancy. Various compositions for use in such diagnosis include PCR primer-probe sets or ligands, labeled or immobilized, which are capable of detecting the changes in expression or translation of these targets.

The invention relates to a method for preparing recombinative reducing peptide, which uses DNA recombinant technology and prepares by gene engineering bacteria invoice method, and especially to the related gene design and synthesis of recombinative reducing peptide, construction of recombinative reducing peptide expression carrier, host conversion with the said expression carrier and construction of the gene engineering bacteria, and fermentation production of recombinative reducing peptide by the said gene engineering bacteria. First an anterior peptide should be designed, in which the peptide can be materials with repetition of one reducing peptide or mixed materials of several reducing peptides. For example, this invention adopts mixed peptides including LRP, LYPVK, AVNPIR, GHKIATFQER and AVPYPQR. Then the representation system pET-28a (+) of bacillus coli BL21 (DE3) is adopted and the amino acid sequence of the anterior peptide is transformed into single stage DNA sequence. Subsequently, the code genes of fused protein comprising this five reducing peptides are designed, the genes are synthesized with chemical method and are connected on the expression carrier, and the suitable positive clone is selected by conversion and determination with optimization fermentation technological condition and technological condition of segregation and decontamination for products, and the obtained recombinative reducing peptide has bioactivity similar to natural materials.

The biased residue of an expressible biased peptide library is conveniently altered, without synthesizing a new DNA mixture, by using a DNA encoding said peptide which includes a suppressible stop codon, said codon encoding the biased residue, whereby the amino acid appearing at the biased position may be altered simply by introducing the same DNA mixture into a different suppressor strain.